[Asia Economy Reporter Yoo Hyun-seok] Hansong Neotek is showing strong performance. It appears that the news confirming that the COVID-19 treatment candidate substance developed by the bio new drug development specialist company 'Modeun Bio', in which Hansong Neotek has invested, maintained drug retention time and half-life in animal Pharmacokinetics (PK) test results, has influenced this trend.
As of 2:53 PM on the 8th, Hansong Neotek was trading at 1,785 KRW, up 4.08% (70 KRW) compared to the previous trading day.
On this day, a media outlet reported that Modeun Bio disclosed additional test results for the related candidate substance MDB-601a-NM, which is being developed as a COVID-19 treatment using a drug delivery system (DDS).
According to the animal PK test results of MDB-601a-NM released by Modeun Bio on the 7th, the blood concentration retention time of the active ingredient Nafamostat was maintained for more than 72 hours, and the half-life was maintained for more than 18 hours. The antiviral substance 601a also showed a blood concentration retention time of more than 48 hours and a half-life of more than 27 hours for Nafamostat.
MDB-601a-NM, developed by Modeun Bio, is a dual-structured drug made by creating nanoparticles of the substance 601, which has proven antiviral and anti-inflammatory effects, and encapsulating Nafamostat inside. It has a dual drug effect treatment mechanism that inhibits intracellular penetration and replication of the coronavirus.
Hansong Neotek participated in and invested in a 1 billion KRW third-party allotment paid-in capital increase conducted by Modeun Bio last year.
Founded in 2008, Modeun Bio is a natural product-based new drug development company. It has established various pipelines including non-alcoholic steatohepatitis, dry age-related macular degeneration, Alzheimer's disease, and multiple sclerosis. It also possesses original DDS technology utilizing natural products.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
